Analysts forecast that Heska Corp (NASDAQ:HSKA) will post sales of $31.65 million for the current quarter, Zacks reports. Two analysts have provided estimates for Heska’s earnings, with the highest sales estimate coming in at $31.67 million and the lowest estimate coming in at $31.63 million. Heska reported sales of $30.38 million in the same quarter last year, which would suggest a positive year over year growth rate of 4.2%. The firm is expected to report its next quarterly earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Heska will report full year sales of $31.65 million for the current year, with estimates ranging from $138.30 million to $138.90 million. For the next financial year, analysts forecast that the firm will post sales of $152.44 million per share, with estimates ranging from $150.54 million to $156.19 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Heska.
Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.07. Heska had a return on equity of 16.23% and a net margin of 7.53%. The company had revenue of $36.04 million for the quarter, compared to analysts’ expectations of $40.56 million. During the same period in the previous year, the firm earned $0.46 EPS. The firm’s revenue was down 8.8% compared to the same quarter last year.
HSKA has been the topic of a number of research analyst reports. Raymond James Financial reissued a “buy” rating on shares of Heska in a report on Monday, December 4th. BidaskClub cut Heska from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Aegis reaffirmed a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Zacks Investment Research cut Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, ValuEngine cut Heska from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $104.08.
Several institutional investors and hedge funds have recently modified their holdings of HSKA. MetLife Investment Advisors LLC purchased a new stake in Heska during the 4th quarter valued at $263,000. Park West Asset Management LLC raised its holdings in Heska by 293.3% during the 4th quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock valued at $27,885,000 after buying an additional 259,256 shares during the period. Redmile Group LLC purchased a new stake in Heska during the 4th quarter valued at $15,753,000. Fred Alger Management Inc. raised its holdings in Heska by 27.3% during the 4th quarter. Fred Alger Management Inc. now owns 139,120 shares of the medical research company’s stock valued at $11,159,000 after buying an additional 29,844 shares during the period. Finally, TimesSquare Capital Management LLC purchased a new stake in Heska during the 4th quarter valued at $23,831,000. 85.92% of the stock is currently owned by institutional investors and hedge funds.
Heska (NASDAQ HSKA) opened at $78.50 on Friday. Heska has a twelve month low of $56.59 and a twelve month high of $115.00. The company has a market capitalization of $570.20, a P/E ratio of 37.52, a P/E/G ratio of 2.16 and a beta of 0.82.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/17/brokerages-anticipate-heska-corp-hska-will-post-quarterly-sales-of-31-65-million.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Get a free copy of the Zacks research report on Heska (HSKA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.